Vertex Pharmaceuticals: Strong Buy Rating Driven by Journavx Approval and Market Expansion Opportunities
Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...
Moderna Stock Is Sliding Wednesday: Here's Why
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
Why MRNA Stock Is Retreating
The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative ...
Moderna slips as Goldman Sachs downgrades on revenue outlook
Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...
Yahoo Finance5d
Why MRNA Stock Is Retreating
The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative direction, according to Goldman analyst Salveen Richter. Consequently ...
Moderna (MRNA) Receives a Hold from Bernstein
In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...
Moderna's stock is falling. Goldman Sachs says it's no longer a buy.
Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.